The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
Thousands of people are staying in temporary shelters following the big earthquake in Indonesia's Aceh province.
Russia appears to have snubbed a Japanese attempt at puppy-love diplomacy by declining a gift of a dog for President Vladimir Putin.
The self-declared white supremacist's was recorded telling an FBI agent "I went to that church in Charleston and I did it."